Following the FDA’s approval of 12 personalised medicines and 7 diagnostics in 2019, then a record number of precision oncology drugs in H1 2020, demand is high for Dx-enabled therapies to reach the market.
Despite the added pressures of the Covid-19 pandemic, in addition to a changing regulatory and fragmented environment, we are seeing significant progresses by pharma, academia and diagnostic expertise towards expediting the development of drugs in areas of great unmet medical need. It is now more important than ever for key stakeholders to come together to share successes and lessons learnt to contextualise on advances and collaborate to deliver therapeutic advances in a more time effective manner.
Providing the platform for this, the Clinical Biomarkers & World CDx Europe returns virtually in 2021 for the 11th year! Uniting 400+ biomarker, diagnostic and precision medicine leaders to advance clinically predictive biomarkers to proven IVDs. Improving patient outcomes and standard of care, this meeting is built for biomarker, translational, clinical, regulatory and commercial functions to tackle end-to-end challenges and deliver successful drug-Dx products.
Plus, this meeting is completely free to attend for Drug Developers, Academics and Researchers!
Secure your complimentary ticket here:
Built with over 40 industry experts, the industry leading speaker line-up includes:
- Thomas Kleen, Chief Scientific Officer, Immodulon Therapeutics
- Clare Balendran, Vice President, Translational Medicine, Novo Nordisk
- Maria Orr, Head of Precision Medicine Biopharmaceuticals, AstraZeneca
- Gerard Sanderink, Global Head Biomarkers & Clinical Bioanalysis, Sanofi
- Alain Van Gool, Head Translational Metabolic Laboratory, Radboudumc
- Andreas Stange, Vice President, TÜV SÜD
- Ellie Corigliano, Head of CDx Cell & Gene Therapies Oncology, GlaxoSmithKline
- Claudia Dollins, Head, Executive Director, Global Regulatory Affairs, Translational Medicine
- & Devices, Merck KGaA
- Christophe Le Tourneau, Head, Department of Drug Development & Innovation (D3i), Institut Curie
- David Crosby, Head of Prevention & Early Detection Research, Cancer Research UK
- Xavier Solé Acha, Head of Unit of Bioinformatics for Precision Oncology, Catalan Institute of Oncology
- Richard Welford, Associate Director & Principal Scientist, Translational Science Biology, Idorsia Pharmaceuticals
- Hugues Malonne, Director General Post-Authorization, Federal Agency for Medicines & Health Products
- Kristiina Rosin, Regulatory Policy & Intelligence Manager, Abbvie
Access your copy of the Full Event Guide for the complete speaker faulty and cutting-edge case studies.
Discover the latest tools and techniques validating biomarker utility, overcoming patient selection challenges in rare disease, key clinical case-study learnings shaping diagnostic strategy in addition to the much needed core EU focus on navigating a tricky regulatory and reimbursement landscape to prevent incoming regulations hindering the delivery of critical drugs to patients in need.
Featuring dynamic panels, 5+ hours of networking, interactive roundtables and not to mention the incredible 45+ expert speakers – there’s no wonder that 113 organisations are already signed up to attend, including:
Abbvie, Achilles Therapeutics, Adverum Biotechnologies, Akari Therapeutics, Alkermes, Astex Pharmaceuticals Inc, AstraZeneca, Barts Cancer Institute, Bayer, Boston Medical Center, Bristol-Myers Squibb, C4X Discovery, Cancer Research UK, Cellestia Biotech AG, Curis Inc., Cyteir, Daiichi Sankyo, European Federation of Pharmaceutical Industries & Associations, Galapagos NV, GlaxoSmithKline, Handl Therapeutics, Idorsia Pharmaceuticals Ltd., Immodulon Therapeutics Ltd, Immunocore Ltd, LG Chem Life Science Innovation Center, LOXO Oncology Inc., Merck KGaA, MRC Laboratory of Molecular Biology, National Institute for Biological Standards & Control – NIBSC, Novartis, Novo Nordisk, Oxford BioTherapeutics, Pfizer, Precision Antibody, Regeneron Pharmaceuticals, Sanofi, Santen Pharmaceuticals, Servier, Sumitomo Dainippon Pharma Co, Syros Pharmaceuticals, Takeda Pharmaceutical Co. Ltd., TÜV SÜD, Vifor Pharma, York Health Economics Consortium
And that is only just scratching the surface!
Don’t miss this important and timely opportunity to re-connect with your global precision medicine peers at this industry leading event! Secure your completely free pass now: www.worldcdxeurope.com/take-part/register/
Follow us on Twitter: @WorldCDx | https://twitter.com/WorldCDx
Join our group on LinkedIn: https://www.linkedin.com/events/11thannualclinicalbiomarkers-wo6753231665604153344/